OTLK
Closed
Outlook Therapeutics Inc
1.58
-0.02 (-1.25%)
Last Update: 01 Jul 2025 23:16:00
Yesterday: 1.6
Day's Range: 1.555 - 1.645
Send
sign up or login to leave a comment!
When Written:
1.03
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative ophthalmic products. The company's lead product candidate, ONS-5010/Lytenava, is a potential treatment for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
ONS-5010/Lytenava is a proprietary formulation of bevacizumab, a well-established anti-vascular endothelial growth factor (anti-VEGF) therapy that has been used off-label to treat wet AMD and DME. Outlook Therapeutics' formulation is designed to be a more stable and consistent version of bevacizumab, with the potential to offer patients a more affordable treatment option.
In addition to ONS-5010/Lytenava, Outlook Therapeutics is also developing other ophthalmic products, including ONS-2030, a long-acting formulation of ranibizumab, another anti-VEGF therapy used to treat wet AMD and DME.
Outlook Therapeutics is headquartered in Cranbury, New Jersey, and was founded in 2011. The company went public in 2018 and is traded on the NASDAQ under the ticker symbol OTLK.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
ONS-5010/Lytenava is a proprietary formulation of bevacizumab, a well-established anti-vascular endothelial growth factor (anti-VEGF) therapy that has been used off-label to treat wet AMD and DME. Outlook Therapeutics' formulation is designed to be a more stable and consistent version of bevacizumab, with the potential to offer patients a more affordable treatment option.
In addition to ONS-5010/Lytenava, Outlook Therapeutics is also developing other ophthalmic products, including ONS-2030, a long-acting formulation of ranibizumab, another anti-VEGF therapy used to treat wet AMD and DME.
Outlook Therapeutics is headquartered in Cranbury, New Jersey, and was founded in 2011. The company went public in 2018 and is traded on the NASDAQ under the ticker symbol OTLK.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!